Back to Trials
NCT07149207PHASE2Recruiting

Intraoperative Molecular Imaging Using ICG for Head and Neck Tumors

Medical University of South Carolina

Start Date

5/4/2026

Completion Date

4/7/2029

Summary

This study is for adult patients with head and neck cancer who are at risk of recurrence. The purpose of this study is to evaluate whether the use of Indocyanine Green (ICG) dye allows for better identification of tumor tissue during surgical procedures. Participation will include standard of care visits along with administration of ICG dye and imaging during surgery. Participation in this study will last approximately 6 weeks.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: 1. Adult subjects at least 18 years of age. 2. Subjects presenting with squamous cell carcinoma of mucosal origin and are at risk for recurrence. 3. Good operative candidate as determined by the treating physician and/or multidisciplinary team. 4. Subject capable of giving informed consent and participating in the process of consent. 5. A WOCBP must be willing and able to use highly effective contraception from the time of informed consent throughout the study period. Acceptable forms of birth control include hormonal contraceptives (such as birth control pills, skin patch, vaginal ring, injection, and/or implant), intrauterine devices (IUDs), and barrier devices (such as condoms, diaphragm, cervical cap, and sponge). Exclusion Criteria: 1. Pregnant or breastfeeding, or expecting to conceive within the projected duration of the study. 2. A WOCBP who has had a positive urine or serum pregnancy test at the time of screening unless: 1. they are menopausal defined by not having a menstrual cycle within the last 12 consecutive months or 2. they have had a hysterectomy. 3. Known allergy to iodides or shellfish. 4. Inadequate organ function at time of screening as defined below: a. Hepatic 1. Total bilirubin \>2 x Institutional Upper Limit of Normal (IULN). Participants with a history of Gilbert's disease must have total bilirubin \<3mg/dL. 2. AST (SGOT) and ALT (SPGT) \>3 x IULN. 5. Currently incarcerated individuals

Interventions

DRUG

Indocyanine Green (ICG)

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)Margin Assessment

Locations

Medical University of South Carolina Hollings Cancer Center

Charleston, South Carolina 29425

United States